{"entity":{"id":"nct06220864","kind":"trial","name":"SNV1521 in Participants With Advanced Solid Tumors","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is recruiting.","summary":"The registry lists NCT06220864 as recruiting, last updated 2026-06-25. Enrolment is 400 planned participants, an estimate. Interventions: SNV1521, DB-1310, Abiraterone, Darolutamide. Primary measures include Safety of SNV1521; Tolerability of SNV1521. No results are posted in the registry; this does not exclude separate publications.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06220864","url":"https://clinicaltrials.gov/study/NCT06220864"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["parp"],"drugs":["snv1521"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06220864","phase":"1","setting":"A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors","sponsor":"Synnovation Therapeutics, Inc.","started":"2024-02-23","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06220864/","neighbours":{"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"snv1521","kind":"drug","name":"SNV1521","route":"/drugs/snv1521/"}]}}